Vaxcyte
PCVX
87 hedge funds and large institutions have $1.06B invested in Vaxcyte in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 6 closing their positions.
167% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 6
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
12% more funds holding
Funds holding: 78 → 87 (+9)
1.94% more ownership
Funds ownership: 82.77% → 84.71% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less capital invested
Capital invested by funds: $1.1B → $1.06B (-$32.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.35M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.99M |
| 3 |
BlackRock
New York
|
+$5.87M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$3.56M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$6.84M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.78M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.69M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.42M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$1.27M |
PCVX Hedge Fund Activity: Q4 2021 in Review
87 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q4 2021, worth a combined $1.06B — down 3% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PCVX positions and 6 closed out — a net gain of 10 holders — while 34 added to existing stakes and 20 trimmed.
The largest buyer was Great Point Partners, adding an estimated $9.35M. The largest seller was Pivotal bioVenture Partners Investment Advisor, cutting an estimated $6.84M.
- 87 institutional investors held Vaxcyte (PCVX) as of Q4 2021, up from 78 in Q3 2021.
- Funds reported $1.06B of Vaxcyte stock for Q4 2021, down 3% quarter-over-quarter.
- 16 funds opened new Vaxcyte positions in Q4 2021 and 6 closed out, a net change of +10 holders.
- The largest Vaxcyte buyer in Q4 2021 was Great Point Partners, an estimated $9.35M added.
- The largest Vaxcyte seller in Q4 2021 was Pivotal bioVenture Partners Investment Advisor, an estimated $6.84M sold.
Based on aggregated 13F filings for Q4 2021.